Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.

Cancer Drug Resist · 2024 · PMC11555183 · PMID 39534873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

10.3 months; HR 0.66; P = 0.043), though the primary endpoint did not reach statistical significance [ 149 ] .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.